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Abstract
The prostaglandin F2α (PGF2α) receptor (FP) is elevated in endometrial adenocarcinoma. This
study found that PGF2α signalling via FP regulates expression of chemokine (C-X-C motif) ligand
1 (CXCL1) in endometrial adenocarcinoma cells. Expression of CXCL1 and its receptor, CXCR2,
are elevated in cancer tissue as compared to normal endometrium and localised to glandular
epithelium, endothelium and stroma. Treatment of Ishikawa cells stably transfected with the FP
receptor (FPS cells) with 100nM PGF2α increased CXCL1 promoter activity, mRNA and protein
expression, and these effects were abolished by co-treatment of cells with FP antagonist or
chemical inhibitors of Gq, EGFR and ERK. Similarly, CXCL1 was elevated in response to 100
nM PGF2α in endometrial adenocarcinoma explant tissue. CXCL1 is a potent neutrophil
chemoattractant. The expression of CXCR2 colocalised to neutrophils in endometrial
adenocarcinoma and increased neutrophils were present in endometrial adenocarcinoma compared
with normal endometrium. Conditioned media from PGF2α-treated FPS cells stimulated
neutrophil chemotaxis which could be abolished by CXCL1 protein immunoneutralisation of the
conditioned media or antagonism of CXCR2. Finally, xenograft tumours in nude mice arising
from inoculation with FPS cells showed increased neutrophil infiltration compared to tumours
arising from wild-type cells or following treatment of mice bearing FPS tumours with CXCL1-
neutralising antibody. In conclusion, our results demonstrate a novel PGF2α-FP pathway that may
regulate the inflammatory microenvironment in endometrial adenocarcinoma via neutrophil
chemotaxis.
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Introduction
Endometrial adenocarcinoma is the most common gynaecological malignancy in Western
countries, affecting mainly post-menopausal women with a frequency of 15-20 per 100 000
women per year (1). Overexpression of the cyclooxygenase (COX) enzymes and
prostaglandins has been demonstrated in endometrial adenocarcinoma as well as a number
of other cancer types and gynaecological pathologies (2, 3).
In the reproductive tract, the most commonly synthesised prostaglandins are the E- and F-
series prostanoids (4). These are synthesised from arachidonic acid by COX enzymes and
prostaglandin synthases, and are then transported out of the cell by a prostaglandin
transporter (5) to act in an autocrine/paracrine manner on G-protein coupled receptors
(GPCR). The GPCR for PGF2α (FP) is a Gq coupled receptor which upon activation leads to
release of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (6). Recently we have
demonstrated a role for FP in endometrial adenocarcinoma, with evidence for elevated
PGF2α-FP signalling upregulating angiogenic and tumourigenic genes including COX-2 (7),
FGF2 (8) and VEGF (9), and increasing proliferation and migration of neoplastic epithelial
cells (10-12).
Chemokine (C-X-C motif) ligand 1 (CXCL1, also known as growth-regulated oncogene α)
has angiogenic, chemoattractant and inflammatory activities (13). A link between
prostaglandins and CXCL1 has been demonstrated, as prostaglandin E2 signalling induces
CXCL1 expression in colorectal cancer cell lines (14). CXCL1 is upregulated in melanoma
(15, 16), colorectal (17, 18) and prostate cancer (19) and binds to the CXCR2 receptor (20)
to promote the recruitment of neutrophils to sites of inflammation (21). Although the role of
neutrophils in cancer is unclear, recent evidence suggests that they may promote tissue
remodelling by production of proteases including MMP-9 (22) and angiogenic factors such
as VEGF (23), in addition to their classical role as the first line of defence against invading
pathogens (24).
In this study, we used a chemokine antibody array to identify CXCL1 as a target gene of
PGF2α. We investigated the expression, localisation and regulation of CXCL1 expression
mediated via PGF2α -FP signalling in endometrial adenocarcinoma and its downstream
regulation of neutrophil influx into endometrial tumours in vitro and in endometrial tumour
xenografts in vivo.
Materials and Methods
Reagents
Indomethacin, PBS, BSA, AL8810, Tri-reagent and PGF2α were purchased from Sigma
Chemical Co. (Dorset, UK). PD98059, AG1478, Cyclosporin A and 4C3MQ were
purchased from Calbiochem (Nottingham, UK). CXCR2 and Gr-1 (a murine neutrophil
marker) antibodies were purchased from R&D systems (Abingdon, UK), and CXCL1 and
neutrophil elastase antibodies from Santa Cruz Biotechnology (Autogen Bioclear, UK) and
DAKO (Cambridgeshire, UK) respectively. FITC-CD11b, PE-GR-1 and Cy5-CD11c
antibodies were obtained from eBioscience (Middlesex, UK). The chemokine antibody array
was purchased from RayBiotech (Peterborough, UK).
Patients and tissue collection
Endometrial adenocarcinoma tissue and normal tissue was obtained as detailed in our prior
studies (9, 10). Cancer patients were pre-diagnosed to have adenocarcinoma of the uterus,
and diagnosis was confirmed histologically in all cases. Normal endometrial tissue was
collected from women undergoing surgery for minor gynecological procedures with no
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underlying endometrial pathology. Ethical approval was obtained from Lothian Research
Ethics Committee and written informed consent was obtained from all subjects before tissue
collection.
Cell lines, culture and treatments
Wild-type Ishikawa cells and Ishikawa cells engineered to stably express the full length
human FP receptor to the levels observed in endometrial adenocarcinomas, referred to as
FPS cells, were cultured as described previously (9). Transient transfections were performed
using Superfect (Qiagen, Crawley, UK) as per the manufacturer's protocol. The optimal
concentrations of all chemical inhibitors and antibodies were determined empirically by
titration using the manufacturer's guidelines as described in our previous studies (25). Cell
viability was determined for each inhibitor using the CellTitre 96 AQueous One Solution
assay (Promega, Southampton, UK) as described in our previous studies (10, 25). Cells were
treated with vehicle, inhibitor alone, or 100 nM PGF2α alone or in the presence of
YM254890 (1 μM), AL8810 (50μM), 43CMQ (1 μM), AG1478 (200 nM) or Cyclosporine
A (1 μM) for the time indicated.
Chemokine antibody array
Conditioned medium (CM) was prepared as described (8). Briefly, FPS cells were
stimulated with vehicle or 100 nM PGF2α for 24 hours. The conditioned medium (V-CM or
P-CM respectively) was analysed for cytokine expression using the RayBio Human
Cytokine Antibody Array 3 kit, following manufacturer's protocol.
CXCL1 luciferase reporter assays
The CXCL1 reporter plasmid consisting of the CXCL1 promoter fused to the firefly
luciferase reporter (as described in (26)) was kindly supplied by Professor Ann Richmond
(Department of Cell Biology, Vanderbilt University School of Medicine, Nashville,
Tennessee). The CXCL1 promoter firefly luciferase reporter was transfected into FPS cells
with pRL-TK (containing the renilla luciferase coding sequence; Promega) as an internal
control. FPS cells were cotransfected with control vector (pcDNA3.0) or vector encoding a
dominant negative isoform of EGFR, Ras, MEK or NFAT (kindly supplied by Professor Zvi
Naor, Tel Aviv University, Israel). The DN constructs have been previously characterised
and described (27, 28). Cells were stimulated with vehicle or 100 nM PGF2α for the time
indicated in the figure legend. The activity of firefly and renilla was determined using the
dual luciferase assay kit (Promega) and total luciferase activity determined relative to the
internal renilla control. Data are expressed as fold increase in luciferase activity as compared
to vehicle treated cells and are presented as mean ± SEM from at least 3 independent
experiments.
Taqman quantitative RT-PCR
CXCL1 and CXCR2 expression in endometrial tissues and FPS cells was measured by
quantitative RT-PCR analysis as described previously (1, 2). FPS cells were treated with
vehicle, 100 nM PGF2α alone or in the presence of inhibitor, or vehicle and inhibitor alone
for 8 hours. RNA samples were then extracted using Tri-reagent following manufacturer's
guidelines. RNA samples were reverse transcribed and RT-PCR performed as described
previously (1, 2) using sequence specific primers and probes: CXCL1 forward, 5′-GTT TTC
AAA TGT TCT CCA GTC ATT ATG-3′; reverse, 5′-CCG CCA GCC TCT ATC ACA
GT-3′; probe, 5′-TTC TGA GGA GCC TGC AAC ATG CCA-3′; CXCR2 forward, 5′-
TGC TCT TCT GGA GGT GTC CTA CA-3′; reverse, 5′-AGA TCT TCA CCT TTC CAG
AAA TCT T-3′; probe, 5′-CCC AGC GAC CCA GTC AGG ATT TAA-3′. Primers and
data were analysed and processed using Sequence Detector v1.6.3 (Applied Biosystems).
Wallace et al. Page 3
Cancer Res. Author manuscript; available in PMC 2010 January 15.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Expression of analyzed genes was normalised to RNA loading for each sample using the
18S ribosomal RNA as an internal standard. Results are expressed as fold increase above
cells treated with vehicle and inhibitor. Data are presented as mean ± SEM from at least 3
independent experiments.
CXCL1 ELISA
CXCL1 protein secretion by FPS cells in the culture media was measured by the Human
CXCL1 Quantikine ELISA kit (R&D systems, Abingdon, UK). FPS cells were treated as
described above for mRNA, for time indicated in the figure legend. The ELISA was then
carried out according to manufacturer's instructions. Optical density of wells was determined
by spectrophotometry at 450 nM. Data are presented as mean ± SEM from at least 3
independent experiments.
Immunohistochemical analysis
Expression of CXCL1, neutrophil elastase, CXCR2 and Gr-1 was localised in endometrial
tissue and xenografts by immunohistochemistry using standard techniques as described
previously (1, 2). Briefly, following antigen retrieval, sections were blocked in 5% normal
rabbit serum (CXCL1 and Gr-1) or normal goat serum (CXCR2 and neutrophil elastase)
diluted in TBS with 5% BSA. Subsequently, tissue sections were incubated with goat anti-
human CXCL1 polyclonal antibody (2 μg/ml), mouse anti-human CXCR2 (5 μg/ml), mouse
anti- human neutrophil elastase monoclonal antibody (2 μg/ml) or rat anti-mouse Gr-1 (5
μg/ml) overnight at 4° C. Control sections included: no primary antibody, non immune goat,
mouse and rat IgG, or CXCL1 antibody pre-absorbed with blocking peptide (20 μg/ml;
Santa Cruz Biotechnology, Autogen Bioclear, UK). Subsequently, sections were incubated
with rabbit anti-goat / rat biotinylated or goat anti-mouse biotinylated antibodies (DAKO,
UK), followed by streptavidin-horse radish peroxidase complex (DAKO). Colour reaction
was developed with 3′3 diaminobenzidine (DAKO). Sections were counterstained in
haemotoxylin. Images were obtained on a PROVIS microscope at x200 or x400
magnification (Olympus Optical, London, UK) using Canon EOS image capture software
(Canon, Woodhatch, Surrey, UK). The number of neutrophils was quantified using
neutrophil elastase staining and standard stereological techniques. Briefly, each section was
examined using x40 plan apo objective from a BH2 microscope (Olympus, Tokyo, Japan)
fitted with an automatic stage (Prior Scientific Instruments Ltd., Cambridge, UK) using a
video camera (HV-C20; Hitachi, Tokyo, Japan) and analyzed with Image-ProPlus 4.5.1
software with a Stereology 5.0 plug-in (Media Cybernetics, Wokingham, Berkshire, UK). A
total of 40 randomised fields of view were examined and counted (n=7 normal
endometrium, n=30 carcinoma) and data are expressed as mean number of cells per mm2 of
tumour examined.
Immunofluorescence microscopy
CXCR2 expression was colocalised with neutrophil elastase by immunofluorescence
microscopy as described previously (8, 29). Briefly, sections were blocked in 5% normal
goat serum diluted in PBS with 5% BSA before incubation with mouse anti-neutrophil
elastase (1 μg / ml). Following overnight incubation at 4°C sections were incubated with
goat-anti mouse biotinylated Fab, then tyramide signal amplification kit (TSA Fluorescein
System, 1:50 dilution, Perkin Elmer, MA). Sections were then microwaved in 0.01M citrate
buffer for 30 minutes and endogenous peroxidise blocked using hydrogen peroxide. Non-
specific binding was blocked with 5% normal goat serum and sections were incubated with
mouse anti-CXCR2 antibody (1 μg/ml) at 4°C overnight. Sections were again incubated
with goat-anti-mouse biotinylated Fab and tyramide signal amplification kit. Nuclei were
stained using ToPro (Molecular Probes, UK). Fluorescent images were visualised and
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photographed using a Carl Zeiss laser scanning microscope LSM510 (x400 objective; Jena,
Germany).
Neutrophil chemotaxis assay
Neutrophil chemotaxis was analysed using transwell inserts (5 μm pore size, Corning
Costar, UK). Neutrophils were purified as previously described (30) and resuspended in
serum free media. 750 000 cells were added to the top chamber of the transwell insert and
600 μl of V-CM or P-CM was added to the bottom chamber. Serum free media alone or
with 50 000 pg/ml CXCL1 were added as negative and positive controls respectively. Cells
were incubated at 37°C in a 5% CO2 atmosphere for 1 hour and the plate was gently tapped
to dislodge cells adhered to the underside of the membrane. Cells in the bottom chamber
were collected and counted at least 6 times using a haemocytometer. Data are expressed as
mean ± SEM from at least 3 independent experiments.
Xenograft tumour model
A suspension of 500 000 Ishikawa wild type (WT) or FPS cells in a total volume of 0.2 ml
DMEM was injected subcutaneously into each dorsal flank of CD1-Foxn1nu mice (Charles
River, UK). The mice (n=30) were divided into two groups of equal tumour size after
engraftment (1 week). The mice were injected twice weekly with 100 μg IgG (WT and FPS)
or CXCL1 neutralising antibody (FPS) via intraperitoneal injection for four weeks. One
tumour from each mouse was placed in PBS for flow cytometry analysis and RNA extracted
from the second tumour from each mouse. The animals were maintained under sterile
conditions in individually vented cages.
Flow cytometry analysis
Xenografts from nude mice were assessed for immune cell infiltrate using flow cytometry
(n=15). Briefly, tumours were digested by collagenase treatment at 37°C for 45 minutes.
Tissue was then mechanically disrupted into a single cell solution using a syringe and 40 μm
mesh and resuspended in FACS wash (PBS + 1%BSA + 2% formalin). Cells were incubated
at 4 °C for 30 minutes in FACS wash containing the following monoclonal antibodies and
appropriate isotype controls: FITC-CD11b, PE-Gr-1 and Cy5-CD11c. Red blood cells were
lysed using BD FACS lysing solution according to manufacturer's instructions (BD
Biosciences, Oxford, UK). Samples were analysed using a FACScalibur cytometer (BD
biosystems) using BD CellQuest software. Neutrophils were defined by expression of Gr-1
and CD11b epitope, absence of CD11c and scatter profile.
Statistical analysis
Where appropriate, data were subjected to statistical analysis with ANOVA and Students t-
test (GraphPad Prism, San Diego, California, USA).
Results
CXCL1 expression in FPS cells
Changes in cytokine expression in FPS cells in response to PGF2α-treatment were examined
by cytokine antibody array (Figure 1A). A combined upregulation of CXCL1, 2 and 3 as
well as CXCL1 alone was observed following 100 nM PGF2α-treatment of FPS cells for 24
hours compared to vehicle treated cells. To verify this finding, the promoter activity (Figure
1B), mRNA (Figure 1C) and protein (Figure 1D) expression of CXCL1 in response to
PGF2α treatment was examined. All were significantly increased (p<0.01) in response to
PGF2α treatment in a time-dependent manner compared to vehicle treated cells.
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Involvement of epidermal growth factor receptor (EGFR) and mitogen-activated protein
kinase kinase (MEK) signalling in CXCL1 production
To determine signalling pathways mediating CXCL1 production in FPS cells, we treated
cells with vehicle, 100 nM PGF2α alone or with a panel of chemical inhibitors of cell
signalling, or inhibitor alone (Figure 2). Treatment of FPS cells with PGF2α for 8 and 24
hours induced a 91.5±8.4 and 22.3±4.7 fold increase in CXCL1 mRNA and protein
expression respectively compared to vehicle treated cells (Figure 2A and 2B). This increase
was abolished by treatment of cells with a selective inhibitor of Gq (YM254890, p<0.01)
and significantly inhibited with the FP receptor antagonist AL8810 (p<0.05) and inhibitors
of EGFR (AG1478, p<0.05) and MEK (PD98059, p<0.01). Inhibitors of calcineurin
(cyclosporine A, CsA) and protein kinase A (PKA; 43CMQ) did not significantly affect
CXCL1 mRNA and protein production.
We confirmed a role for EGFR and extracellular signal-regulated kinase (ERK) in PGF2α
mediated CXCL1 production by co-transfecting FPS cells with the CXCL1 promoter and
either an empty vector (pcDNA3.0) or dominant negative (DN)-EGFR, DN-Ras, DN-MEK
or DN-Nuclear factor of activated T-cells (NFAT; Figure 2C). Treatment of control-vector
transfected cells with 100 nM PGF2α showed an elevation of CXCL1 promoter activity of
18.9±3.6 fold which was significantly reduced by co-transfection of cells with DN-EGFR
(p<0.05), DN-ras (p<0.01) and DN-MEK (p<0.01), but no significant difference was shown
when cells were transfected with DN-NFAT.
CXCL1 and CXCR2 expression in endometrial adenocarcinoma and normal endometrium
Since we had ascertained a role for the FP receptor in regulating CXCL1 in an endometrial
adenocarcinoma cell line we next investigated the expression and regulation of CXCL1 in
endometrial adenocarcinoma explants by PGF2α. Quantitative RT-PCR analysis showed an
increase in the expression of CXCL1 and its receptor CXCR2 mRNA expression in human
endometrial adenocarcinoma tissue (n=58) compared to normal endometrium (n=45; 5.9 and
4.2 fold respectively; Figure 3A and 3B; p<0.001). We investigated whether CXCL1
expression in endometrial adenocarcinoma explants was regulated via FP and MEK
signalling pathways. Carcinoma tissue was treated with PGF2α in the absence/presence of
AL8810 and PD98059 for 24 hours. CXCL1 mRNA was found to be elevated 5.3 ±0.8 fold
in response to PGF2α (p<0.05). Co-treatment of tissue with AL8810 or PD988059
significantly reduced this increase in CXCL1 expression (p<0.05).
Localisation of CXCL1 and CXCR2 in endometrial adenocarcinoma
The site of expression of CXCL1 and CXCR2 protein in carcinoma tissue was then
determined by immunohistochemistry (Figure 4A). CXCL1 and CXCR2 immunoreactivity
was localised to glandular epithelium, vascular endothelial cells and stroma in all well,
moderately and poorly differentiated carcinoma sections studied (n=4 each group).
Using serial sectioning, CXCL1 expression could be localised to the same glandular
epithelial and vascular endothelial cells as the FP receptor (Figure 4B; highlighted by
arrowheads). CXCL1 has been previously described as a potent neutrophil chemoattractant.
We next colocalised CXCR2 expression throughout the stroma with expression of neutrophil
elastase, a neutrophil marker, in endometrial adenocarcinoma using dual
immunofluorescence immunohistochemistry (Figure 4C). No immunoreactivity was
observed in sections incubated with non-immune IgG. The number of neutrophils present in
endometrial tissue was then quantified using immunohistochemistry for neutrophil elastase
(Figure 4D) and was found to be 13.9±2.3 fold higher in cancer compared to sections of
normal endometrium (p<0.01).
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PGF2α-stimulated CXCL1 induces neutrophil chemotaxis in vitro and in vivo
We next determined whether the CXCL1 expressed in FPS cells via PGF2α-FP receptor
interaction could induce neutrophil chemotaxis. Human neutrophils were purified from
peripheral blood and used in a chemotaxis assay. We found a significant increase in
neutrophil chemotaxis in response to conditioned media from FPS cells treated with 100 nM
PGF2α (P-CM) as compared to vehicle treated cells (V-CM) (Figure 5A). This effect was
significantly inhibited with immunoneutralisation of CXCL1 prior to incubation with
neutrophils or with the addition of the CXCR2 antagonist SB225002 to P-CM (p<0.001).
To explore whether FP receptor signalling could promote neutrophil migration in vivo we
injected WT or FPS cells subcutaneously in nude mice. Mice were then regularly injected
with control IgG (WT and FPS xenografts) or CXCL1 antibody (FPS xenografts). Tumours
formed from FPS cells expressed significantly higher CXCL1 mRNA as compared to WT
tumours (Figure 5B) and when analysed by flow cytometry, had increased neutrophil
infiltration (Figure 5C, p<0.001). This infiltration was significantly decreased in FPS
xenografts injected with CXCL1 neutralising antibody compared to those treated with non-
immune IgG (p<0.001). This analysis was confirmed further by immunohistochemistry
(Figure 5D), where increased neutrophils were seen distributed throughout FPS xenografts
as compared to WT or CXCL immunoneutralised FPS xenografts.
Discussion
The link between inflammation and tumour progression has been demonstrated in a range of
studies. For example, elevated expression of inflammatory COX-2 and prostaglandins has
been correlated with tumour growth and angiogenesis in prostate, pancreatic and colon
cancer (31-33), and the risk of long term inflammation has been demonstrated by studies
showing that continued use of specific COX-2 inhibitors (NSAIDS) can significantly reduce
cancer occurrence in patients at high risk (34). In the present study we demonstrate that
PGF2α-FP signalling can regulate expression of the inflammatory chemokine CXCL1 in
endometrial adenocarcinoma cells to modulate neutrophil influx in tumours. To our
knowledge, this is the first study to provide a link between inflammatory prostanoids,
specifically PGF2α, and neutrophil recruitment in endometrial cancers.
Prostaglandins have been demonstrated to regulate chemokine expression in vitro (35, 36).
Prostaglandin E2 (PGE2) is overexpressed in many cancer types and has been shown to
induce CXCL1 production in colon cancer cells which can then promote tube formation and
migration of endothelial cells (14). We have previously ascertained a role for the FP receptor
and PGF2α signalling in regulating endometrial adenocarcinoma (8-11). In the present study,
we investigated a role for the FP receptor in modulating the expression of chemokines using
an in vitro model system of Ishikawa cells stably expressing the human FP receptor (FPS
cells) (9) and a human cytokine antibody array. The array identified CXCL1 as a key
cytokine induced by PGF2α-FP signalling. Using FPS cells, which we have previously
shown to reproduce the ex vivo effects of PGF2α on endometrial adenocarcinoma tissue
explants (9), we elaborated the signalling pathways mediating the role of FP on CXCL1
expression using chemical inhibitors and dominant negative mutants of cell signalling
pathways. A key effector pathway which has been previously shown to regulate
tumourigenic signalling molecules in response to GPCR signalling is the MAPK pathway.
The signalling components of this pathway in FPS cells have been identified in our
laboratory, where the phosphorylation of the downstream component of the MAPK
pathway, ERK1/2, was demonstrated to be mediated by EGFR trans-activation and c-src
phosphorylation (9). We found that chemical inhibitors of EGFR and MEK could inhibit
CXCL1 production, as did co-transfection of dominant negative EGFR, Ras and MEK.
However NFAT, a common regulator of cytokine expression (37), was not involved in
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PGF2α mediated CXCL1 production in this cell type. This data is supported by previously
published evidence in colorectal adenocarcinoma cell lines where the ERK pathway was
also demonstrated to be crucial in the regulation of CXCL1 expression after stimulation with
PGE2 (14).
Overexpression of CXCL1 has previously been demonstrated in a variety of tumour types,
including colorectal (18) and melanoma (15), and promotes a variety of cellular functions
including cell proliferation in oesophageal cancer (38) and cell invasion in bladder cancer
(39). Here we demonstrated elevated expression of CXCL1 and its receptor CXCR2 in
endometrial adenocarcinoma compared to normal endometrium. Expression of both was
localised to glandular epithelium, stroma and vascular endothelial cells. In addition,
treatment of endometrial adenocarcinoma explants with PGF2α caused an increase in
CXCL1 expression via FP receptor and ERK1/2 signalling pathways confirming the
importance of this signalling cascade in regulating CXCL1 expression ex vivo. CXCR2
localisation in neutrophils in endometrial adenocarcinoma suggested that CXCL1 via
CXCR2 could play a role in immune cell function. A role for CXCL1 in neutrophil influx
has been previously shown in an angiogenic sponge model in the mouse, as endogenous
CXCL1 expression increased immediately preceding a neutrophil influx (40).
Here we show by immunohistochemistry that neutrophils are elevated in human endometrial
adenocarcinomas. We have also confirmed that CXCL1 is strongly chemotactic to
neutrophils as conditioned media from PGF2α-stimulated FPS cells induced chemotaxis of
peripheral neutrophils. This chemotaxis was significantly reduced by CXCL1 immuno-
neutralisation and CXCR2 inhibition using a specific antagonist. In order to determine a role
for CXCL1 induced by PGF2α-FP interaction in vivo we inoculated nude mice with FPS and
WT cells. The increased neutrophils in the resulting FPS tumours as compared to WT were
significantly reduced by injection of CXCL1 neutralising antibodies, demonstrating that
PGF2α signalling via CXCL1 is influencing neutrophil cell infiltrate in endometrial
adenocarcinomas. Neutrophil infiltration into tumours has also been demonstrated to be
dependent on CXC chemokine-CXCR2 signalling in a model of melanoma in a CXCR2 null
nude mouse (41).
A chemokine-mediated influx of neutrophils is seen in the late secretory phase of the normal
endometrium (42). Their role may be dependent on the activating agents and cytokines
present, but they are thought to be involved in the breakdown and repair at menstruation by
degranulation and the release of proteases which degrade the extracellular matrix (43). They
may also be capable of remodelling vasculature, as neutrophils found close to or associated
with endothelial microvessels express VEGF during or coincident with angiogenesis in the
normal menstrual cycle (44).
The role of neutrophils in endometrial adenocarcinoma is unclear and in our study, similar to
other reports (45, 46) neutrophil influx in our xenograft model did not impact on tumour
size. However, considering their profound tissue-remodelling capabilities, which have been
demonstrated in a number of animal models of other cancer types it is possible that they play
a similar role in endometrial cancer. For example, neutrophils have been shown to uniquely
produce a TIMP-free MMP-9, a key protease involved in extracellular matrix degradation
which may affect the tumour microenvironment by tissue remodelling (24). In addition, the
depletion of neutrophils in a mouse model was demonstrated to prevent metastasis of
fibrosarcoma cells from the primary tumour (45), suggesting a role for neutrophils in the
switch to a metastatic phenotype. In a nude mouse model of breast cancer, overexpresssion
of IL-8, a chemokine related to CXCL1, caused an infiltration of neutrophils which
increased invasiveness of the tumour, likely due to an increase in protease production (47).
Similarly, the decrease in neutrophil infiltration caused by an inhibition of CXCL1
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expression in a nude mouse model of colon cancer significantly decreased metastasis in
these animals (48). Furthermore, neutrophils may also promote tumourigenesis through
means other than tissue remodelling. In an in vitro model of colon cancer, neutrophils
promote cellular stress by inducing transient errors in DNA replication in epithelial cells
(49), which could ultimately lead to carcinogenesis, whilst neutrophils from ovarian cancer
patients released higher levels of reactive oxygen species which could potentially lead to
cellular changes which support tumour progression (50).
In conclusion, we provide evidence for a novel PGF2α-FP pathway which can regulate the
inflammatory microenvironment in endometrial adenocarcinoma via CXCL1 induced
neutrophil chemotaxis.
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Figure 1.
PGF2α regulates CXCL1 expression in FPS cells. A: A human cytokine antibody array was
used to determine differences in protein production in the conditioned media of vehicle
treated and PGF2α treated cells. B: CXCL1 promoter activity was increased in FPS cells
stimulated with 100 nM PGF2α as compared to vehicle control over a period of 4 to 24
hours. Data are expressed as fold increase in luciferase activity as compared to vehicle
treated cells. C: FPS cells stimulated with 100 nM PGF2α show a time dependent increase in
CXCL1 mRNA expression as measured by quantitative RT-PCR. Data are expressed as fold
over vehicle treated cells. D: CXCL1 protein secreted into media was measured by ELISA
and was increased after treatment with PGF2α up to 72 hours. (Columns: mean of at least 3
independent experiments. P<0.05: b is significantly different to a, P<0.01: c is significantly
different from a and b)
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Figure 2.
CXCL1 production in FPS cells is mediated by EGFR, Ras and MEK. A: CXCL1 mRNA
production, measured by quantitative RT-PCR, was increased after 8 hours PGF2α
treatment. This was decreased by co-treatment with YM254890, AL8810, AG1478, and
PD98059. No reduction was seen after co-treatment with CsA or 4C3MQ. B: CXCL1
protein secretion after 24 hours PGF2α treatment was reduced after co-treatment with
YM254890, AL8810, AG1478, and PD98059. No reduction was seen after co-treatment
with CsA or 4C3MQ C: CXCL1 promoter activity was measured in cells treated with
PGF2α alone or with DN-EGFR, DN-Ras, DN-MEK or DN-NFAT. Significant reduction in
activity was seen after 8 hours with all constructs except DN-NFAT. (Columns: mean of at
least 3 independent experiments, **p<0.01)
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Figure 3.
CXCL1 and CXCR2 expression is increased in endometrial adenocarcinoma. A: CXCL1
and B: CXCR2 mRNA expression is significantly increased in endometrial adenocarcinoma
tissue (n = 58) as compared to normal endometrium (n = 45). C: CXCL1 mRNA is increased
in endometrial adenocarcinoma explants (n=4) after treatment with PGF2α. Co-treatment
with AL8810 or PD98059 significantly decreases this effect. (P<0.05: b is significantly
different to a, P<0.001: d is significantly different from a and b)
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Figure 4.
CXCL1 and CXCR2 are expressed in endometrial adenocarcinoma and colocalise with FP
receptor expression and neutrophil elastase respectively. A: Immunohistochemical staining
of CXCL1 and CXCR2 in moderately and poorly differentiated endometrial
adenocarcinoma. GL – glandular, VE = vascular endothelial, S = stromal. B: CXCL1 can be
colocalised to the same cells as FP receptor (shown by arrowheads) in well differentiated
adenocarcinoma by serial sectioning. C: Co-localisation of the site of expression of CXCR2
(green) and neutrophil elastase (red). Negative controls are inset. D: Carcinoma sections
(n=30) and normal proliferative endometrium (n=7) were analysed for expression of
neutrophil elastase. Increased expression was seen in cancer (b is significantly different to a;
P<0.01). Scale bars in A and B represent 100 μm, in C represent 10 μm.
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Figure 5.
Neutrophils migrate in response to PGF2α induced CXCL1 in vitro and in vivo. A:
Neutrophil chemotaxis was increased in response to conditioned media from FPS cells
treated with PGF2α for 48 hours (P-CM) as compared to vehicle treated cells (V-CM).
CXCL1 immunoneutralisation and the addition of 60 nM SB-225002 significantly decreased
chemotaxis. Control goat IgG immunoneutralisation showed no significant effect. Data are
expressed as fold over negative control (serum free medium). B: CXCL1 mRNA expression
is significantly increased in nude mice xenografts formed from FPS cells as compared to
WT cell xenografts. Injection of CXCL antibody into xenografts made no significant
difference to CXCL1 mRNA expression. C: Percentage of neutrophils in tumours from WT
and FPS xenografts (n=5 per group), measured by flow cytometry. Increased neutrophil
infiltration is seen in FPS xenografts, which is significantly reduced by injection of CXCL1-
neutralising antibody. D: Localisation of neutrophils in xenografts by Gr-1 staining.
Neutrophils are highlighted by arrowheads, scale bars indicate 100 μm (p<0.05: b is
significantly different to a, P<0.01: c is significantly different from a and b, P<0.001: d is
significantly different from a, b, and c.)
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